Literature DB >> 6829493

A phase II study of alanosine in advanced large bowel carcinoma.

J Rubin, V Hineman, C G Moertel, A J Schutt, R G Hahn.   

Abstract

Thirty patients with advanced metastatic colorectal adenocarcinoma were treated with alanosine at a dose of 160 mg/m2 daily for 5 days every 4 weeks. Sixteen patients had received no prior chemotherapy and 14 had been previously treated with one or more cytotoxic agents. No patient met the criteria for a complete or partial response. The major toxicity was stomatitis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6829493     DOI: 10.1097/00000421-198304000-00009

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  3 in total

1.  Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.

Authors:  D D Von Hoff; S J Green; J A Neidhart; C Fabian; T Budd; J F Boyd; C K Osborne
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

Review 2.  Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies.

Authors:  Joseph R Bertino; William R Waud; William B Parker; Martin Lubin
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

3.  A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.

Authors:  Hedy Lee Kindler; Howard A Burris; Alan B Sandler; Ira Anton Oliff
Journal:  Invest New Drugs       Date:  2008-07-11       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.